The products can be bought on the internet!
The Government of India launched
“National Protocol of Clinical Management based on Ayurveda and Yoga for the management of Covid 19”,
prepared by the national working group in consensus with various expert committees.
An interdisciplinary Ayush R&D team was formed by the Ayush Ministry to represent the Indian Council of Medical Research (ICMR), the All India Institute of Medical Sciences (AIIMS), the Scientific and Industrial Research Council (CSIR)), the Department of Biotechnology (DBT) and the Ayush institutions.
The interdisciplinary working group Ayush R&D has designed and formulated clinical research protocols for prophylactic studies and additional interventions in Covid 19 positive cases for the study of four different interventions, namely:
- Guduchi + Pippali and
- a multi-plant based formulation – AYUSH-64.
AYUSH-64 and Kabasur Kudineer have been identified for treatment with Covid-19.
The results of clinical trial research have illustrated the effectiveness of AYUSH-64 in treating asymptomatic and mild cases as independent and for managing mild and moderate Covid 19 as an adjunct to standard care.
AYUSH-64 showed a significant improvement in clinical recovery as an adjunct treatment to Standard Care.
Furthermore, Kabasur Kudineer, a siddha preparation, has also been used in clinical trials to study efficacy in Covid-19 patients by the Siddha Central Research Council (CCRS) of the Ministry of Ayush.
This has proven useful in the treatment of mild to moderate Covid 19 infection.
To provide the maximum benefit of Ayush medical systems, a nationwide campaign was initiated to distribute AYUSH-64 and Kabasura Kudineer through the National Institutes and Research Councils of the Ayush Ministry across the country.
The ministry issued orders to all Ayush authorizing authorities of the states/drug controllers and expert committees there to allow manufacturers authorized for AYUSH-64 under their jurisdiction to include new indications of AYUSH-64.
This is intended for reuse as an intervention for the management of asymptomatic, mild to moderate Covid 19, in addition to existing indications, and to speed up the process of licensing / approval of such applications for the manufacture of the drug AYUSH-64, provided that the prescribed standards and the relevant provisions of the Cosmetics and Regulations are met, 1945.
To date, 37 production facilities in 11 states have been transferred to AYUSH-64 technology by CCRAS through the National Research Development Corporation (NRDC).
The ministry of Ayush has formed an Interdisciplinary Technical Review Committee (ITRC) for Covid 19. It is for the purpose of examining patent and patented applications/claims (P&P)ASU&H drugs/ASU classics and
H drugs with new indication or reuse of licensed P&P, ASU &H for Covid 19 licensed medicines, transmitted by state authorities / individuals mentioned by the Drug Policy Section of the Ministry of Ayush.
So far, the following applications have been approved in ITRC regarding Covid 19 claims: –
The Divya Coronil tablet of the Patanjali Research Foundation Trust, Haridwar, Uttarakhand – recommended as a support measure in the management of Covid 19 without claiming healing.
Clevira tablet by M/s Apex Laboratories Private Ltd., Tamilnadu has been recommended as a support measure for mild to moderate Covid 19 status.
Kabasura Kudineer from Sri Sri Tattva, Sriveda Sattva Pvt. Ltd. Bangalore has been recommended as an intervention for prevention and mild to moderate symptoms of Covid 19.
According to requests received from state/UT governments on the use of Ayush National Mission (NAM) funds for the purchase of drugs, including the drug AYUSH-64, in the context of the Covid 19 pandemic, an amount of Rs. 2271,551 Lakh has been approved by the Ayush Ministry.